Viking Therapeutics, Inc.
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
Poster Presentations Highlight Baseline Characteristics from the Phase 3 VANQUISH-2 Trial of Subcutaneous VK2735 and the Impact of VK2735 on Obesity…